# Fate Therapeutics Names Jamie Harrell to Lead Commercialization of CAR T-Cell Therapies

- URL: https://stocks.freetheai.org/news/fate-therapeutics-names-jamie-harrell-to-lead-commercialization-of-car-t-cell-9ccd93
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:FATE](https://stocks.freetheai.org/symbols/NASDAQ-FATE)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Fate Therapeutics, Inc. (FATE) appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026. In this newly created executive role, Harrell will direct commercial strategy across the company's oncology and autoimmune programs as the biopharmaceutical firm prepares to advance its cell therapy candidates toward potential market approval.

Harrell brings over 25 years of commercial industry experience, having previously held executive roles at Aurinia Pharmaceuticals, Avalo Therapeutics, and Covidien. His background includes overseeing the commercial rollout of lupus nephritis treatments and establishing in-office infusion models. Fate Therapeutics plans to leverage his expertise to build a physician engagement model that expands access to off-the-shelf CAR T-cell therapies in community healthcare settings.

Investors will be watching how Harrell shapes market preparation for key clinical assets, including FT819, which is in a Phase 2 trial for refractory lupus nephritis, and FT839, currently in a Phase 1/2 trial for conditions such as rheumatoid arthritis. Following the management announcement, shares of Fate Therapeutics traded at $2.18, up 2.35% on the day.

## Key points

- Fate Therapeutics appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations.
- Harrell brings more than 25 years of experience, including commercial leadership roles at Aurinia Pharmaceuticals and Avalo Therapeutics.
- The new role focuses on preparing commercial strategies for off-the-shelf CAR T-cell therapies across oncology and autoimmune indications.
- Key pipeline assets being targeted include FT819 in a Phase 2 trial for lupus nephritis and FT839 in Phase 1/2 testing.

## Questions and answers

### Who did Fate Therapeutics hire as Senior Vice President of Commercial Operations?

Fate Therapeutics appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026.

### What will Jamie Harrell oversee at Fate Therapeutics?

Harrell will lead market development and commercial strategy for the company's autoimmune and oncology cell therapy programs, including FT819 and FT839.

### What clinical trials is Fate Therapeutics currently conducting for its cell therapies?

The company is evaluating FT819 in a Phase 2 trial for refractory lupus nephritis and FT839 in a Phase 1/2 trial across multiple autoimmune indications, including rheumatoid arthritis.